An Indian diabetes drug to treat type 2 diabetics is approaching the final stages of creatio, according to reports from the country. A successful round of final clinical trials would give India their first ever intellectual property in the pharmaceutical field.
The drug is joint manufactured by Dr Reddy’s and Rheoscience, and is now hitting phase III clinical trials. To treat type 2 diabetics, the drug is called Balagliatzone.
If Bala passes the last stage of clinical testing, India will finally occupy a place in the world of drug discovery. The drug, if it comes to market, will be the first original product patent in this field.
India is one of the countries most affected by diabetes. The erosion of traditional diet and lifestyle has led to a soaring type 2 diabetes population.